Intellia Therapeutics Files 8-K
Ticker: NTLA · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1652130
Sentiment: neutral
Topics: 8-K, corporate-disclosure, financial-reporting
TL;DR
Intellia Therapeutics filed an 8-K on 10/27/25 covering Reg FD, other events, and financials.
AI Summary
Intellia Therapeutics, Inc. filed an 8-K on October 27, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company's principal executive offices are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts.
Why It Matters
This 8-K filing provides updates on Intellia Therapeutics' corporate activities and financial reporting, which are important for investors to monitor the company's status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.
Key Numbers
- 001-37766 — SEC File Number (Identifies Intellia Therapeutics' filings with the SEC.)
- 36-4785571 — IRS Employer Identification No. (Tax identification number for Intellia Therapeutics.)
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- October 27, 2025 (date) — Date of earliest event reported
- 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139 (location) — Address of principal executive offices
- 001-37766 (company_id) — SEC File Number
FAQ
What specific events are disclosed under 'Other Events' in this 8-K filing?
The provided text does not detail the specific 'Other Events' but indicates this category is included in the filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 27, 2025.
What is the primary business of Intellia Therapeutics, Inc. based on its SIC code?
Based on its SIC code [2835], Intellia Therapeutics, Inc. is involved in 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
Where are Intellia Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.
What is the fiscal year end for Intellia Therapeutics, Inc.?
The fiscal year end for Intellia Therapeutics, Inc. is December 31 (1231).
Filing Stats: 1,167 words · 5 min read · ~4 pages · Grade level 15.2 · Accepted 2025-10-27 08:01:28
Key Financial Figures
- $0.0001 — ich registered Common Stock (Par Value $0.0001) NTLA The Nasdaq Global Market Ind
Filing Documents
- d44351d8k.htm (8-K) — 33KB
- d44351dex991.htm (EX-99.1) — 13KB
- g44351dsp6.jpg (GRAPHIC) — 37KB
- 0001193125-25-250757.txt ( ) — 216KB
- ntla-20251027.xsd (EX-101.SCH) — 3KB
- ntla-20251027_lab.xml (EX-101.LAB) — 18KB
- ntla-20251027_pre.xml (EX-101.PRE) — 11KB
- d44351d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated October 27, 2025 titled "Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Forward-Looking Statements
Forward-Looking Statements This current report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations regarding: the safety, tolerability, efficacy, success and advancement of its clinical programs for "nex-z" (also known as NTLA-2001), including the ability to resume and successfully complete its MAGNITUDE and MAGNITUDE-2 trials for nex-z. Any forward-looking statements in this current report on Form 8-K are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to Intellia's ability to resume the MAGNITUDE and MAGNITUDE-2 trials, the implications of this event on the safety and efficacy of nex-z and further development of nex-z; regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; the risk that any one or more of Intellia's product candidates, including nex-z, will not be successfully developed and commercialized; risks related to Intel
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Intellia Therapeutics, Inc. (Registrant) Date: October 27, 2025 By: /s/ John M. Leonard Name: John M. Leonard Title: Chief Executive Officer and President